Search

Displaying results 1301 - 1310 of 10000 in total
  1. Drug

    Desloratadine

    go.drugbank.com/drugs/DB00967
    ApprovedInvestigational

    Desloratadine is a second generation, tricyclic antihistamine that which has a selective and peripheral H1-antagonist action. … It is the active descarboethoxy metabolite of loratidine (a second generation histamine).

    Mixtures: NEUMOLEX® NFProducts: DESLORATADIN 1A PHAR 5MG
  2. Drug

    NUC B1000

    go.drugbank.com/drugs/DB05242
    Experimental

    NUC B1000 is an expressed interfering RNA (eiRNA)- based product consisting of a plasmid DNA construct designed to produce four short interfering RNA (siRNA) molecules, formulated with a proprietary cationic-lipid … [F3910] eiRNA is an approach to RNAi therapeutics, whereby a plasmid DNA coding for desired dsRNA is delivered to diseased cells enabling the cells to carry out dsRNA production internally thereby invoking

  3. Drug

    Yellow fever vaccine

    go.drugbank.com/drugs/DB10805
    ApprovedInvestigational

    The World Health Organization no longer recommends the use of a 10-year booster dose following primary immunization, as a single dose is "sufficient to confer life-long immunity against yellow fever disease … Yellow fever vaccine prevents against Yellow Fever, a viral hemorrhagic disease caused by the transmission of a _flavivirus_ through the bite of an infected mosquito.

    Synonyms: Yellow fever virus live antigen, A
  4. Drug

    Sparsentan

    go.drugbank.com/drugs/DB12548
    ApprovedInvestigational

    >A</sub>R and 0.8 nM for AT<sub>1</sub>R). … Sparsentan is a dual antagonist of the endothelin type A receptor (ET<sub>A</sub>R) and the angiotensin II (Ang II) type 1 receptor (AT<sub>1</sub>R) with a similar affinity for both (9.3 nM for ET<sub

    Categories: Dual Endothelin Type A Receptor/Ang II Subtype 1 Receptor Antagonist (DEARA)
  5. Drug

    Bempedoic acid

    go.drugbank.com/drugs/DB11936
    ApprovedInvestigational

    High levels of LDL cholesterol (LDL-C) are a major risk factor for cardiovascular events. … [L12180] Bempedoic acid is first-in-class adenosine triphosphate-citrate lyase (ACL) inhibitor used once a day for reducing LDL cholesterol levels in statin-refractory patients.

  6. Drug

    Plicamycin

    go.drugbank.com/drugs/DB06810
    ApprovedWithdrawn

    Plicamycin is an antineoplastic antibiotic produced by Streptomyces plicatus.

    Categories: Compounds used in a research, industrial, or household setting
  7. Drug

    Turoctocog alfa pegol

    go.drugbank.com/drugs/DB14738
    ApprovedInvestigational

    Fundamentally, the N8-GP moiety is identical to [turoctocog alfa], a recombinant human clotting factor VIII (rFVIII) with a truncated B-domain made from the sequence coding for 10 amino acids from the … The essential difference between turoctocog alfa and N8-GP, however, is the specific attachment of a 40-kDa polyethylene glycol (PEG) group to a specific _O_-glycan in the truncated B-domain of the general

    Synonyms: N8-GP, Turoctocog alfa pegol, N8-GP
  8. Drug

    Dalbavancin

    go.drugbank.com/drugs/DB06219
    ApprovedInvestigational

    Dalbavancin is a second-generation lipoglycopeptide antibiotic that was designed to improve on the natural glycopeptides currently available, such as vancomycin and teicoplanin [A4072, A4073]. … Modifications from these older glycoprotein classes facilitated a similar mechanism of action for dalbavancin but with increased activity and once-weekly dosing [FDA Label, F2356, A4072, A4073].

  9. Drug

    Tioguanine

    go.drugbank.com/drugs/DB00352
    ApprovedInvestigational

    An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia.

  10. Drug

    Moxisylyte

    go.drugbank.com/drugs/DB09205
    Approved

    Moxisylyte, denominated as thymoxamine in the UK, is a specific and orally active α1-adrenergic antagonist.